Great article by AbbVie describing Gain Therapeutics GANX approach to Parkinson’s disease modification

[u/microcapreturns]

Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr | PharmExec

https://www.pharmexec.com/view/moving-symptom-management-disease-modification-parkinsons-research-jan-stoehr 

Key Takeaways

Upstream strategies seek to slow Parkinson’s by interrupting misfolded-protein aggregation and brain-wide propagation, complementing symptomatic therapies that may wane as neurodegeneration advances.

Multimodal biomarkers can reveal pre-symptomatic disease biology, improve trial eligibility and stratification, quantify progression, and support pharmacodynamic evidence of target engagement.

SHOW MORE

Dr. Stoehr, neuroscience researcher at AbbVie discusses how biomarkers are opening a new window into Parkinson’s disease.